Jury Finds Axonics Did Not Infringe Any of Three Patents-in-Suit
By Connor Hart
A jury unanimously found that Axonics did not infringe any of the three patents-in-suit brought against the company by Medtronic in a patent infringement lawsuit in the U.S. District Court for the Central District of California.
Chief Executive Raymond Cohen said Wednesday that the Irvine, Calif., medical technology company's "proprietary tined lead design and temperature sensor technology is differentiated" from Medtronic's intellectual property.
"As we have said since this case was first filed in late 2019, our view is that Medtronic's lawsuit was initiated to stifle competition, limit patient and physician choice, and protect the incumbent's monopoly in sacral neuromodulation," he said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
September 18, 2024 19:39 ET (23:39 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk
United States